

CURRICULUM VITAE

Gerald W. Dorn II, M.D.

DATE UPDATED: September 16, 2019

Philip and Sima K. Needleman Professor of Medicine
Associate Chair for Translational Research
Director, Center for Pharmacogenomics
Washington University School of Medicine
Box 8220, 660 South Euclid Avenue
St. Louis, MO 63110 USA
Phone: 314 362-4892
FAX: 314 362-8844
Phone: 314 362-4892 (office) 513 532-0812 (cell)
email: gdorn@wustl.edu



President and Founder
Mitochondria in Motion, Inc.
Suite 216, 4340 Duncan Avenue
St. Louis, MO 63110 USA
email: gdorn@mimdrugs.com

PERSONAL DATA

Birthdate: August 7, 1958; Monterey, CA
Marital Status: Married; Deborah Ann Hauger, M.D., FACC
Children: Lisa Elizabeth Dorn; DOB: December 27, 1992
Home Address: 4440 Lindell Blvd, #1202 St. Louis, MO 63108

EDUCATION

<u>Year</u>	<u>Degree</u>	<u>Institution</u>
1977	B.S. Biology	Lander College, Greenwood, SC
1981	M.D.	Medical University of South Carolina, Charleston, SC

POST-GRADUATE TRAINING

<u>Year</u>	<u>Position</u>	<u>Institution</u>
1981-1982	Intern in Internal Medicine	Medical University of South Carolina Charleston, SC
1982-1984	Resident in Internal Medicine	Medical University of South Carolina Charleston, SC
1984-1985	Fellow in Pharmacology	Medical University of South Carolina Charleston, SC
1985-1988	Fellow in Cardiology	Medical University of South Carolina Charleston, SC

Gerald W. Dorn II, MD
ACADEMIC APPOINTMENTS

University of Texas Health Science Center, San Antonio, TX

1988-1990	Assistant Professor	Department of Medicine
1989-1990	Director	Cardiac Catheterization Laboratory Audie L. Murphy Memorial Veterans Hospital

University of Cincinnati

1990-1993	Assistant Professor	Department of Medicine Department of Pharmacology & Cell Biophysics
1993-1999	Associate Professor with Tenure	Department of Medicine Department of Pharmacology & Cell Biophysics
1995-1998	Director	Cardiovascular Fellowship Training Program Division of Cardiology
1995-1998	Director	Cardiac Catheterization Laboratory Cincinnati Veterans Administration Medical Center
1998-1999	Director	Cardiopulmonary Molecular Pharmacology Program
1999-2008	Professor	Department of Medicine
1999-2004	Division Director	Division of Cardiology
2003-2004	Director	Heart and Vascular Center
2003-2005	Associate Dean for Cardiovascular Services	College of Medicine
2005-2008	Director	Center for Molecular Cardiovascular Research
2005-2008	Professor	Department of Pediatrics

Washington University School of Medicine

2008-present	Philip and Sima K Needleman Professor Associate Chair for Translational Research	Department of Internal Medicine
2008-present	Director	Center for Pharmacogenomics

LICENSURE AND CERTIFICATION

<u>Year</u>	<u>Institution or State</u>
1982-2017	South Carolina License #10907
1984	American Board of Internal Medicine
1987	American Board of Internal Medicine Subspecialty of Cardiovascular Disease
1988-2018	Texas License #H4904
1990	Ohio License #35-06-0148
2008	Missouri License #2008011532

Gerald W. Dorn II, MD**PROFESSIONAL MEMBERSHIPS**

Association of American Physicians
 American Society for Clinical Investigation
 Alpha Omega Alpha
 American College of Cardiology, Fellow
 American Heart Association, Fellow, Council on Circulation
 American Clinical and Climatological Association
 Heart Failure Society of America
 International Society for Heart Research

HONORS AND AWARDS

1970	Eagle Scout, Boy Scouts of America Troop 234, Point Mugu, Calif.
1974-1977	Patterson Pre-Medical Scholar, Lander Fellow
1976-1977	Alpha Chi Honor Society
1984	M.U.S.C. Institutional Research Fellowship, National Research Service Award
1989	Lyndon Baines Johnson Research Award, AHA, Texas Affiliate
1992-1997	Established Investigator of the American Heart Association
1995	American Heart Association Council on Circulation Cardiovascular Prize
1998	American Society for Clinical Investigation
1999	Plenary Speaker, American Heart Association 72 nd Scientific Sessions
2000-2003	Mable Stonehill Chair in Medicine
2000-2006	ASCI Institutional Representative, University of Cincinnati
2002	Alpha Omega Alpha Honor Society
2003-2008	Hanna Chair in Cardiology, University of Cincinnati
2006	Gordon Wilson Lecturer, American Clinical and Climatological Association
2009	Association of American Physicians
2009-present	Philip and Sima K. Needleman Professor
2010	Co-Chair, AHA Basic Cardiovascular Sciences Annual meeting
2010	3 rd Annual John Ross, Jr., MD Lecture in Cardiology, UCSD
2010	Ralph Major Lecture in Internal Medicine, Kansas University
2011	Speaker, Excellence in Basic Science, 15 th Annual HFSA Scientific Meeting
2011	Chair, Myocardial Ischemia and Metabolism Study Section, NHLBI
2011	Thomas W. Smith Memorial Lecture, AHA Scientific Sessions 2011
2013	Plenary Speaker, American Heart Association Scientific Sessions 2013
2014	Invited mentor, Cardiac Regulatory Mechanisms Gordon Research Seminar
2014	Distinguished Scientist Award of the American Heart Association
2014	“Best manuscript award” Song, et al, <i>Circulation Research</i> 2014
2015	Co-Chair, Keystone meeting on Mitochondria, Metabolism, and Heart Failure
2015	Keith Reimer Distinguished Lecturer, International Society Heart Research 2015
2016	John Foerster Distinguished Lecturer, University of Manitoba Institute of Cardiovascular Sciences
2017	Keynote Lecture, Sarnoff Cardiovascular Research Foundation 37 th annual scientific meeting, Boston MA
2017	Keynote Lecture, EMBO workshop “Mitochondrial Quality Control”, Xi’an, China.
2019	Harrington Scholar-Innovator awardee.
2019	Keynote Speaker, 3 rd JCS Forum on Basic Cardiovascular Research, Tokyo Japan

Gerald W. Dorn II, MD**EDITORIAL BOARD MEMBERSHIP**

<i>Science</i> , Board of Reviewing Editors	2011-present
<i>Physiological Reviews</i>	2010-2019
<i>Circulation Research</i>	1996-2014
<i>Circulation Research</i> , Board of Consulting Editors	2014-2019
<i>Current Opinion in Physiology</i>	2018-present
<i>Circulation</i>	1994-2015
<i>Journal of Clinical Investigation</i>	2008-2011
<i>Journal of Biological Chemistry</i>	2001-2006

RESEARCH ADVISORY COMMITTEES (2000-present)

Abstract Reviewer, American Heart Association National Scientific Meeting (1999-present)

Member, NIH CVA/ CCHF Study Section (2000-2004)

Member, NIH Site Visit for University of Colorado GCRC Renewal (2001)

Member, NIH PPG Special Review Committee “Genomic Studies of Cardiac Remodeling and Failure” NHLBI (2002)

Member, Scientific Advisory Panel, Donald W. Reynolds Foundation Cardiovascular Clinical Research Programs (2002-2003)

Member, Scientific Committee, The La Jolla-Rome-Yamaguchi Research Conferences on Cardiac Function (2002-2005)

Member, NIH PPG Special Review Committee “Genomic Studies of Cardiac Remodeling and Failure” NHLBI (2003)

Chairman, NIH Special Emphasis Panel “Cardiac Adrenergic Receptors in Hypertrophy” (2004)

Member, NIH Special Emphasis Panel “Extramural Loan Repayment Program for Clinical and Pediatric Researchers” NHLBI (2005)

Member, NIH PPG Special Review Committee, Longevity and Stress Resistance, NIA (2005)

Ad Hoc Reviewer, NIH Cardiac Hypertrophy and Heart Failure Study Section (2005)

Member, NIH PPG Review Committee "Genesis and Treatment of Heart Failure in the Young" (2005)

NHLBI Strategic Planning Group (Level 1), Heart Failure and Cardiomyopathy (2006)

Member, NIH PPG Special Review Committee, Longevity and Stress Resistance, NIA (2006)

Member, NIH PPG Review Committee "Genesis and Treatment of Heart Failure in the Young" (2006)

Temporary Member, NIH K99/R00 Mentored Scientist Award (2006)

Temporary Member, NIH K99/R00 Mentored Scientist Award (2007)

Signaling in Hypertrophy and Failure Interest Group Program Committee, ISHR (2009-2010)

Reviewer, Norman Hackerman Advanced Research Program, Texas Higher Education Board (2010)

NHLBI/ORD workshop: “Strategic Planning for Pulmonary Vascular Disease Research (2010)

Member, NHLBI Myocardial Ischemia and Metabolism Study Section (2009-2012)

Member, AHA Cardiovascular Genome-Phenome Studies Advisory Panel (2014)

Co-Chair, AHA Cardiovascular Genome-Phenome Studies Review Committee (2014)

Temporary Member, NIA Cellular Mechanisms in Aging and Development Study Section (2015)

Member, NIH Transformative R01 (TR01) Study Section (2015-2017)

Member, NHLBI Outstanding investigator award (R35) Study Section (2017, 2018)

Gerald W. Dorn II, MD**DISSERTATION COMMITTEES**

<u>Name</u>	<u>Department</u>	<u>Years</u>
Haesun Kim	Pathology	1993-1996
Brian Oliver	Pathology/Medicine	1997-1998
Nicole Tepe	Pharmacology and Cell Biophysics	1997-2000
Mark Williams	Pharmacology and Cell Biophysics	1997-2000
Qiu-Jing Song (Co-Chair)	Pharmacology and Cell Biophysics	2001-2004
Kimberly Gregory	Pharmacology and Cell Biophysics	2001-2005
Bryan Mitton (Co-Chair)	Pharmacology and Cell Biophysics	2004-2007
Theresa Okeyo-Owuor	Div of Biology & Biomedical Sciences	2011-2013
Maria Trissal	Div of Biology & Biomedical Sciences	2012-2014
Moshi Song (Chair)	Div of Biology & Biomedical Sciences	2013-2016
Rong Zeng	Div of Biology & Biomedical Sciences	2015-2016
Anna Ballard	Div of Biology & Biomedical Sciences	2016-

GRADUATE QUALIFYING COMMITTEES

Vivek Kadambi	Pharmacology and Cell Biophysics	1994
Saadia Ahmed	Pharmacology and Cell Biophysics	1994
Metiner Tosun	Pharmacology and Cell Biophysics	1995
Sheryl Koch	Pharmacology and Cell Biophysics	1995
Nicole Tepe	Pharmacology and Cell Biophysics	1997

UNDERGRADUATE THESIS EVALUATIONS

Xin Paul Wei Harvard University Program in Life Sciences

PROMOTIONS AND TENURE COMMITTEES

Ronglih Liao, PhD Harvard Medical School

Gerald W. Dorn II, MD**OTHER COMMITTEES/LEADERSHIP POSITIONS****University of Cincinnati**

Member, College of Medicine Space Committee (2000-2001)

Member, Health Alliance of Greater Cincinnati Cardiovascular Service Line Committee (2000-2003)

Director, Human Gene Identification, Expression and Analysis (HuGe IdEA) initiative (2000-2004)

Chair, College of Medicine Cardiopulmonary Millennium Project Planning Committee (2000)

Member, College of Medicine Dean's Clinical Council (2002-2004)

Washington University

Member, Institute for Clinical and Translational Sciences Executive Committee (2008-2016)

Chair, Center for Pharmacogenomics Advisory Committee (2008)

Distinguished Investigator Award Selection Committee (2009-2011)

National Organizations

Program Committee, Heart Failure Society of America (2002-2004)

Publications Committee, Heart Failure Society of America (2009-2011)

Board of Directors Member at Large, the Society for Translational Science (2010-2012)

Program Co-Chair for Genetics, American Heart Association Committee on Scientific Sessions Program (CSSP) (2011, 2013)

Fall Program Committee Chair (2012-2015), AHA Council on Basic Cardiovascular Sciences

Katz Award Committee (2013-present), AHA Council on Basic Cardiovascular Sciences

Committee Vice-Chair (2013-2015), AHA BCVS Committee for Scientific Sessions Planning

Committee Co-Chair (2013-2015), CSSP Leadership committee, AHA Council on BCVS

AHA BCVS Council Leadership Committee (2015-2017)

Gerald W. Dorn II, MD
POSTDOCTORAL TRAINEES

University of Cincinnati

Safdar Ali, MD	1992-1994
Drew D'Angelo, PhD	1993-1997
John Collins, MD	1993-1994
Karamchand Paul, MD	1994-1996
William Houser, MD	1994-1996
Jacob Cheu, PhD	1995
Yoshihito Sakata, MD, PhD	1996-1997
Guangyu Wu, PhD	1999-2001
Tsuyoshi Toyokawa, MD	1999-2001
Harvey Hahn, MD	1999-2000
Thomas Barrett, PhD	2000-2001
Martin Yussman, MD	2000-2002
Faisal Syed, M.D.	2002-2003
Anita Galvez, PhD	2003-2006
Scot Matkovich, PhD	2005-2010

Washington University in St. Louis

Yun Chen, PhD	2009-2013
Casey Jowdy, PhD	2010-2011
Peter Hecker, PhD	2012-2013
Guohua Gong, PhD	2013-2015
Julie Fleischer, MD	2015-2016
Agostinho Rocha, PhD	2016-2018
Antonietta Franco, PhD	2016-2019
Xiawei Dang, PhD	2018-present
Jijia Li, PhD	2018-present

Gerald W. Dorn II, MD

8

MENTOR GRANT AWARDS

American Heart Association Fellowship Award. "Characterization of Promoter Elements which Regulate the Thromboxane Receptor" Drew D. D'Angelo, Ph.D. Direct costs: \$25,000. 94-95.

American Heart Association Fellowship Award. "Phosphorylation and Desensitization of Thromboxane Receptors" William A. Houser, M.D. Direct costs: \$30,000. 7/1/95-6/30/96.

American Heart Association Boots Award. "Structural and Functional Characterization of Human Thromboxane Receptor Gene" Recipient - Drew D. D'Angelo, Ph.D. Direct costs: \$25,000. 1995

American Heart Association Fellowship Award. "Interaction of Aids and Cocaine on Force Interval Behavior and Beta Adrenergic Receptor Responsiveness" Harvey S. Hahn, M.D. Direct costs: \$30,000. 7/1/99-6/30/99.

National Institutes of Health. 5T32 HL07382-25 - "Training in Cardiovascular Biology" (Arnold Schwartz, PI) Martin G. Yussman, M.D. Direct costs: \$46,139. 7/1/01-6/30/02.

American Heart Association Fellowship Award. 0225236B - "Mitochondrial Death Protein, Nix, in Apoptotic Cardiomyopathy" Faisal Syed, M.D. Direct costs: \$30,000. 7/1/02-6/30/03.

National Institutes of Health. K08 KL71939 – "Protein Kinase C α as a Determinant of Cardiac Adrenergic Response" Harvey Hahn, M.D. Direct costs: \$629,937. 02/01/04-01/31/09.

American Heart Association Predoctoral Fellowship Award. "Mitochondrial dynamics, quality control, and cardiac homeostasis." Moshi Song. Direct costs: \$52,000. 1/1/14-12/31-15.

McDonnell Center for Cellular and Molecular Neurobiology Fellowship Award. "Small molecules for therapeutic targeting of mitofusins in neurodegenerative disease." Antonietta Franco, PhD. Direct costs: \$30,000. 7/1/17-6/30/18.

MENTOR RESEARCH AWARDS

Harvey Hahn MD, Third place, *Protein Kinase C α Determines In Vivo Myocardial β -Adrenergic Responsiveness*. AstraZeneca Young Investigator Competition, San Francisco, Ca, 2002.

Abhinav Diwan MD, First place, Junior Faculty Basic Science Research. *Nix, a Bcl2 Protein, is Essential for Maintenance of Cardiomyocyte Calcium Stores and for Apoptosis During Erythroblast Maturation*. Northwestern Cardiovascular Young Investigator's Forum, Chicago, Il, 2006.

Faisal Syed MD, Co-winner, Samuel A. Levine Young Clinical Investigator Award, *Genetic β -blockade: A G-protein Coupled Receptor Kinase-5 Polymorphism that Inhibits β -adrenoreceptor Signaling is Protective in Heart Failure*. American Heart Association National Meetings, 2006.

Abhinav Diwan MD, Finalist, Louis N and Arnold M Katz Basic Science Research Prize for Young Investigators, *Nix in the Heart: Regulation of Developmental Apoptosis and Sarcoplasmic Reticular Calcium Stores Explains its Functional Diversity*. American Heart Association National Meetings, 2006.

Yun Chen, PhD, Late Breaking Basic Science (oral), *A Parkin-Mitofusin Interaction Directs Cardiac Mitochondrial Culling Independent of Mitochondrial Fusion*. AHA Scientific Sessions, 2011.

Moshi Song, NHLBI Scholar, *Hypertrophic Cardiomyopathy Caused by a Rare Mitofusin 2 Mutation*. Keystone Symposium on Cardiac Remodeling, Signaling, Matrix and Heart Function, 2013.

Yun Chen, PhD, Late Breaking Basic Science (Poster), *Aggravation of Mitophagic Cardiomyopathy by Highly Expressed Mitochondrial Catalase Reveals the Essential Function of Mitochondrial-generated Ros in Mitophagy*. AHA Scientific Sessions, 2013.

Moshi Song, Late Breaking Basic Science (Oral), *Fulminant Lethal Cardiomyopathy Reveals Essential Roles of Organelle Fission/Fusion in Cardiomyocyte Mitochondrial Regeneration*. AHA Scientific Sessions, 2013.

Moshi Song, 2015 *Barbara Jakschik Awardee* for Washington University Division of Biological and Biomedical Sciences outstanding female graduate student whose thesis focused on the area of metabolic regulation.

Moshi Song, 2016 *Spencer T. and Ann W. Olin Fellow* recognized for “past achievement and the promise of a distinguished career in the biomedical sciences”; an Olin Fellowship is the highest award accorded a doctoral student by Washington University in St. Louis.

Gerald W. Dorn II, MD**CURRENT GRANT SUPPORT**

NIH R35 HL135736 NHLBI Outstanding investigator award -

The mitochondrial dynamism/fitness/biogenesis interactome in cardiac disease.

PI – Gerald W. Dorn II. Total Costs: \$6,405,000 1/1/2017-12/31/2023.

Muscular Dystrophy Association MDA628906 Research Grant -

Mitofusin agonists to treat Charcot-Marie-Tooth Disease.

PI- Gerald W Dorn II. Total Costs: \$267,942 8/1/2019-7/31/2021

NIH R41 NS113642 NINDS STTR Phase I –

Mitofusin agonists to treat neurodegenerative disease.

PI – Gerald W Dorn II. Total Costs: \$452,121 11/1/2019-10/31/2021

PENDING GRANT SUPPORT

NIH R41 NS115184 NINDS STTR Phase I –

Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A

PI – Gerald W Dorn II. Total Costs: \$237,747 Pending (score 14)

NIH U44 NS116889 Blueprint Neurotherapeutics Network: Small Molecule Drug Discovery

Mitofusin agonists to treat Charcot-Marie-Tooth disease Type 2A

PI – Sriram Devanathan; co-PI – Gerald W Dorn II. Total Costs: \$3,499,091

PREVIOUS NIH GRANT SUPPORT

R01 HL128071 – *Linking cell death and mitochondrial quality control mechanisms in heart disease.*

Co-PIs – Gerald W. Dorn II and Richard N. Kitsis. Total Costs: \$2,612,690 2015-2019.

R01 HL 128441 – *Molecular orchestration of mitochondrial fitness via replacement or repair*

PI - Gerald W. Dorn II. Total Costs: \$1,525,000 04/01/2016-03/31/2020 (relinquished for R35)

R01 HL059888 – *Mitochondrial Fusion Factors and Cardiomyopathy.*

PI - Gerald W. Dorn II. Total Costs: \$1,881,760 08/13/2013 – 05/31/2018 (relinquished R35).

R01HL087871– *G-Protein-Dependent and –Independent Kinase Signaling in Cardiac Hypertrophy*

PI - Gerald W. Dorn II. Total Costs: \$2,348,808 12/01/2012 – 1/31/2017 (relinquished for R35).

R01 HL108943 – *MicroRNA Targeting in Heart Failure.*

PI - Gerald W. Dorn II. Total Costs: \$1,520,000 12/15/2011 – 11/30/2015.

R21 HL 107276 – *Mitochondrial Manipulation and Analysis in Drosophila Hearts.*

PI - Gerald W. Dorn II. Total Costs: \$418,000 8/01/2011 – 4/30/2013.

R01 HL080008 - *Calpains as Mediators of Cardiac Ischemic Injury.*

PI - Gerald W. Dorn II. Total Costs: \$1,863,311 8/01/2006- 7/31/2011.

RC2 HL 102222 – *CTRIP: Genetic Testing to Individualize Management of Common Heart Diseases.*

PI - Gerald W. Dorn II. Total Costs: \$1,905,001 9/01/2010 – 8/31/2011.

P50 HL 077101 – *Genetic and Molecular Signaling in Heart Failure.*

PI - Gerald W. Dorn II. Total Costs \$20,471,934 01/01/2005 – 12/31/2009

R01 HL 069779 – *Rab GTPase Protein Transport in Heart Disease.*

PI - Gerald W. Dorn II. Total Costs \$1,264,005 06/06/2002 – 03/31/2007.

R01 HL 058010 – *Phospholipase C and Cardiac Hypertrophy.*

PI - Gerald W. Dorn II. 08/15/1998 – 07/31/2006.

P50 HL 052318 – *Specialized Center of Research in Heart Failure.*

PI - Gerald W. Dorn II. 10/01/1995 – 01/31/2005.

R01 HL 049267 – *Megakaryocyte Development and Coronary Disease.*

Gerald W. Dorn II, MD

PI - Gerald W. Dorn II. 08/01/1993 – 03/31/2000.

11

SCIENTIFIC PUBLICATIONS:

1. **Dorn GW II**, Baldwin JG Jr. Rapid development of myeloma in a patient with Hodgkin's disease. *J SC Med Assoc* 80:599-600, 1984.
2. **Dorn GW II**, Sens D, Chaikhouni A, Mais D, Halushka PV. Cultured human vascular smooth muscle cells with functional thromboxane A₂ receptors: Measurement of U46619-induced ⁴⁵Calcium efflux. *Circ Res* 60:952-956, 1987.
3. **Dorn GW II**, Burch RM, Kochel PJ, Mais DE, Halushka PV. Decrease in agonist affinity for human platelet thromboxane A₂/prostaglandin H₂ receptors induced by a platelet-derived supernatant. *Biochem Pharmacol* 36:1913-1917, 1987.
4. **Dorn GW II**, Donner R, Assey ME, Spann JF Jr, Wiles HB, Carabello BA. Alterations in left ventricular geometry, wall stress and ejection performance after correction of congenital aortic stenosis. *Circulation* 78:1358-1364, 1988.
5. Leman RB, Spinale FG, **Dorn GW II**, Cooper G, Spann JF Jr, Gillette PC, Carabello BA. Supernormal ejection performance is isolated to the ipsilateral congenitally pressure-overloaded ventricle. *J Am Coll Cardiol* 13:1314-1319, 1989.
6. **Dorn GW II**, Gertler AS, Gordon L, Usher BW, Hendrix GH. Left ventricular dysfunction in symptomatic mitral valve prolapse. *Chest* 95:370-373, 1989.
7. **Dorn GW II**. Distinct platelet thromboxane A₂/prostaglandin H₂ receptor subtypes: A radioligand binding study of human platelets. *J Clin Invest* 84:1883-1891, 1989.
8. **Dorn GW II**, DeJesus A. Binding of an [¹²⁵I] labelled thromboxane A₂ prostaglandin H₂ receptor agonist to baboon platelets. *Prostaglandins* 38:645-653, 1989.
9. **Dorn GW II**. Isoelectric and mass characterization of human platelet thromboxane A₂ prostaglandin H₂ receptors. *Biochem Biophys Res Commun* 163:183-188, 1989.
10. **Dorn GW II**, Liel N, Trask JL, Mais DE, Assey ME, Halushka PV. Increased platelet thromboxane A₂/prostaglandin H₂ receptors in patients with acute myocardial infarction. *Circulation* 81:212-218, 1990.
11. **Dorn GW II**. Cyclic oxidation-reduction reactions regulate thromboxane A₂/prostaglandin H₂ receptor number and affinity in human platelet membranes. *J Biol Chem* 265:4240-4246, 1990.
12. **Dorn GW II**, DeJesus A. Human platelet aggregation and shape change are coupled to separate thromboxane A₂-prostaglandin H₂ receptors. *Am J Physiol* 260:H327-H334, 1991.
13. **Dorn GW II**. Tissue- and species-specific differences in ligand binding to thromboxane A₂ receptors. *Am J Physiol* 261:R145-R153, 1991.
14. **Dorn GW II**. Mechanism for homologous downregulation of thromboxane A₂ receptors in cultured human chronic myelogenous leukemia (K562) cells. *J Pharmacol Exp Ther* 259:228-234, 1991.
15. Jones CL, Witte DP, Feller MJ, Fugman DA, **Dorn GW II**, Lieberman MA. Response of a human megakaryocytic cell line to thrombin: Increase in intracellular free calcium and mitogen release. *Biochim Biophys Acta* 1136:272-282, 1992.
16. **Dorn GW II**, Becker MW. Growth factors downregulate vascular smooth muscle thromboxane receptors independent of cell growth. *Am J Physiol* 262:C927-C933, 1992.
17. **Dorn GW II**. Regulation of response to thromboxane A₂ in CHRF-288 megakaryocytic cells. *Am J Physiol* 262:C991-C999, 1992.
18. **Dorn GW II**, Davis MG. Differential megakaryocytic desensitization to platelet agonists. *Am J Physiol* 263:C864-C872, 1992.

SCIENTIFIC PUBLICATIONS (cont.)

19. **Dorn GW II**, Becker MW, Davis MG. Dissociation of the contractile and hypertrophic effects of vasoconstrictor prostanoids in vascular smooth muscle. *J Biol Chem* 267:24897-24905, 1992.
20. **Dorn GW II**, Davis MG. Thrombin, but not thromboxane, stimulates megakaryocytic differentiation in human megakaryoblastic leukemia cells. *J Pharmacol Exp Ther* 262:1242-1247, 1992.
21. **Dorn GW II**, Becker MW. Thromboxane A₂ stimulated signal transduction in vascular smooth muscle. *J Pharmacol Exp Ther* 265:447-456, 1993.
22. Ali S, Davis MG, Becker MW, **Dorn GW II**. Thromboxane A₂ stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. *J Biol Chem* 268:17397-17403, 1993.
23. Williams SP, **Dorn GW II**, Rapoport RM. Prostaglandin I₂ mediates contraction and relaxation of vascular smooth muscle. *Am J Physiol* 267:H796-H803, 1994.
24. **Dorn GW II**, Davis MG, D'Angelo DD. Gene expression during phorbol ester-induced differentiation of cultured human megakaryoblastic cells. *Am J Physiol* 266:C1231-1239, 1994.
25. **Dorn GW II**, Robbins J, Ball N, Walsh RA. Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice. *Am J Physiol* 267:H400-H405, 1994.
26. Davis MG, Ali S, Leikauf GD, **Dorn GW II**. Tyrosine kinase inhibition prevents deformation-stimulated vascular smooth muscle growth. *Hypertension* 24:706-713, 1994.
27. D'Angelo DD, Davis MG, Ali S, **Dorn GW II**. Cloning and pharmacologic characterization of a thromboxane A₂ receptor from K562 (human chronic myelogenous leukemia) cells. *J Pharmacol Exp Ther* 271:1034-1041, 1994.
28. Bowling N, Dube GP, Kurtz WL, Brune KA, Saussy DL Jr, **Dorn GW II**, Mais DE. Characterization of thromboxane A₂/prostaglandin H₂ binding sites in guinea pig cardiac membrane preparations. *J Mol Cell Cardiol* 26:915-923, 1994.
29. Ali S, Becker MW, Davis MG, **Dorn GW II**. Dissociation of vasoconstrictor-stimulated basic fibroblast growth factor expression from hypertrophic growth in cultured vascular smooth muscle cells: Relevant roles of protein kinase C. *Circ Res* 75:836-843, 1994.
30. Ali S, **Dorn GW II**. Patterns of tyrosine phosphorylation differ in vascular hypertrophy and hyperplasia. *Am J Physiol* 267:C1674-C1681, 1994.
31. D'Angelo DD, Davis MG, Houser WA, Eubank JJ, Ritchie ME, **Dorn GW II**. Characterization of 5' end of human thromboxane receptor gene: Organizational analysis and mapping of protein kinase C-responsive elements regulating expression in platelets. *Circ Res* 77(3):466-474, 1995.
32. Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, **Dorn GW II**, Lightfoot P, German R, Howles PN, Kier A, O'Toole BA, Sasse J, Gonzalez AM, Baird A, Doetschman TC. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. *Mol Biol Cell* 6:1861-1873, 1995.
33. Lenihan DJ, Gerson MC, **Dorn GW II**, Hoit BD, Walsh RA. Effects of changes in atrioventricular gradient and contractility on left ventricular filling in human diastolic cardiac dysfunction. *Am Heart J* 132:1179-1188, 1996.
34. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, **Dorn GW II**, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. *J Clin Invest* 97(2):533-539, 1996.

SCIENTIFIC PUBLICATIONS (cont.)

35. Guteski-Hamblin AM, Song G, Walsh RA, Frenzke M, Boivin GP, **Dorn GW II**, Kaetzel MA, Horseman ND, Dedman JR. Annexin VI overexpression targeted to heart alters cardiomyocyte function in transgenic mice. *Am J Physiol* 270:H1091-H1100, 1996.
36. D'Angelo DD, Eubank JJ, Davis MG, **Dorn GW II**. Mutagenic analysis of platelet thromboxane receptor cysteines: Roles in ligand binding and receptor-effector coupling. *J Biol Chem* 271(11):6233-6240, 1996.
37. D'Angelo DD, Oliver BG, Davis MG, McCluskey TS, **Dorn GW II**. Novel role for Sp1 in phorbol ester enhancement of human platelet thromboxane receptor gene expression. *J Biol Chem* 271(33):19696-19704, 1996.
38. D'Angelo DD, Terasawa T, Carlisle SJ, **Dorn GW II**, Lynch KR. Characterization of a rat kidney thromboxane A₂ receptor: High affinity for the agonist ligand I-BOP. *Prostaglandins* 52:303-316, 1996.
39. Collins JF, Pawloski-Dahm C, Davis MG, Ball N, **Dorn GW II**, Walsh RA. The role of the cytoskeleton in left ventricular pressure overload hypertrophy and failure. *J Mol Cell Cardiol* 28:1435-1443, 1996.
40. Qian J, Hendrix M, Larsen WJ, **Dorn GW II**, Lessard JL. Establishment and characterization of a conditionally immortalized smooth muscle/myometrial-like cell line. *Mol Reprod Dev* 47:284-294, 1997.
41. Paul K, Ball NA, **Dorn GW II**, Walsh RA. Left ventricular stretch stimulates angiotensin II--mediated phosphatidylinositol hydrolysis and protein kinase C ϵ isoform translocation in adult guinea pig hearts. *Circ Res* 81:643-650, 1997.
42. Oral H, **Dorn GW II**, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor- α in the adult mammalian cardiac myocyte. *J Biol Chem* 272(8):4836-4842, 1997.
43. **Dorn GW II**, Davis MG, D'Angelo DD. Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (TP) receptors: Analysis of chimeric rat/human TP receptors. *J Biol Chem* 272(19):12399-12405, 1997.
44. **Dorn GW II**, Oswald KJ, McCluskey TS, Kuhel DG, Liggett SB. α_{2A} -adrenergic receptor stimulated calcium release is transduced by G_i-associated G _{$\beta\gamma$} -mediated activation of phospholipase C. *Biochemistry* 36(21):6415-6423, 1997.
44. Davis MG, Zhou M, Ali S, Coffin JD, Doetschman T, **Dorn GW II**. Intracrine and autocrine effects of basic fibroblast growth factor in vascular smooth muscle cells. *J Mol Cell Cardiol* 29(4):1061-1072, 1997.
45. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, **Dorn GW II**. Transgenic G α_q -overexpression induces cardiac contractile failure in mice. *Proc Natl Acad Sci USA* 94:8121-8126, 1997.
46. Chu G, **Dorn GW II**, Luo W, Harrer JM, Kadambi VJ, Walsh RA, Kranias EG. Monomeric phospholamban overexpression in transgenic mouse hearts. *Circ Res* 81:485-492, 1997.
47. Sato Y, Ferguson DG, Sako H, **Dorn GW II**, Kadambi VJ, Yatani A, Hoit BD, Walsh RA, Kranias EG. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. *J Biol Chem* 273:28470-28477, 1998.

SCIENTIFIC PUBLICATIONS (cont.)

48. Sakata Y, Hoit BD, Liggett SB, Walsh RA, **Dorn GW II**. Decompensation of pressure-overload hypertrophy in $G\alpha_q$ -overexpressing mice. *Circulation* 97:1488-1495, 1998.
49. Pawloski-Dahm CM, Song G, Kirkpatrick DL, Palermo J, Gulick J, **Dorn GW II**, Robbins J, Walsh RA. Effects of total replacement of atrial myosin light chain-2 with the ventricular isoform in atrial myocytes of transgenic mice. *Circulation* 97:1508-1513, 1998.
50. Liang M, Eason MG, Jewell-Motz EA, Williams MA, Theiss CT, **Dorn GW II**, Liggett SB. Phosphorylation and functional desensitization of the α_{2A} -adrenergic receptor by protein kinase C. *Mol Pharmacol* 54:44-49, 1998.
51. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, **Dorn GW II**. Enhanced $G\alpha_q$ Signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. *Proc Natl Acad Sci USA* 95:10140-10145, 1998.
52. Yatani A, Frank K, Sako H, Kranias EG, **Dorn GW II**. Cardiac-specific overexpression of $G\alpha_q$ alters excitation-contraction coupling in isolated cardiac myocytes. *J Mol Cell Cardiol* 31:1327-1336, 1999.
53. Tepe NM, Lorenz JN, Yatani A, Dash R, Kranias EG, **Dorn GW II**, Liggett SB. Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: Enhanced basal catalytic activity and function without increased cardiomyocyte β -adrenergic signalling. *Biochemistry* 38:16706-16713, 1999.
54. Small K, Feng JF, Lorenz J, Donnelly ET, Yu A, Im MJ, **Dorn GW II**, Liggett SB. Cardiac specific overexpression of transglutaminase II (G_h) results in a unique hypertrophy phenotype independent of phospholipase C activation. *J Biol Chem* 274:21291-21296, 1999.
55. Sah VP, Minamisawa S, Tam SP, Wu TH, **Dorn GW II**, Ross J Jr, Chien KR, Brown JH. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. *J Clin Invest* 103(12):1627-1634, 1999.
56. **Dorn GW II**, Souroujon MC, Liron T, Chen CH, Gray MO, Zhou HZ, Csukai M, Wu G, Lorenz JN, Mochly-Rosen D. Sustained in vivo cardiac protection by a rationally designed peptide that causes ϵ protein kinase C translocation. *Proc Natl Acad Sci USA* 96:12798-12803, 1999.
57. **Dorn GW II**, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low- and high-level transgenic expression of β_2 -adrenergic receptors differentially affect cardiac hypertrophy and function in $G\alpha_q$ -overexpressing mice. *Proc Natl Acad Sci USA* 96:6400-6405, 1999.
58. Wu G, Toyokawa T, Hahn H, **Dorn GW II**. ϵ Protein Kinase C in Pathological Myocardial Hypertrophy: Analysis by combined transgenic expression of translocation modifiers and $G\alpha_q$. *J Biol Chem* 275:29927-29930, 2000.
59. Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, Abraham WT, Chenier TC, **Dorn GW II**, Liggett SB. Polymorphisms of the β_2 -adrenergic receptor determine exercise capacity in patients with heart failure. *Circ Res* 86:834-840, 2000.
60. Mochly-Rosen D, Wu G, Hahn H, Osinska H, Liron T, Lorenz JN, Yatani A, Robbins J, **Dorn GW II**. Cardirotrophic effects of protein kinase C ϵ : Analysis by in vivo modulation of PKC ϵ translocation. *Circ Res* 86:1173-1179, 2000.
61. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, **Dorn GW II**. Early and delayed consequences of β_2 -adrenergic receptor overexpression in mouse hearts: Critical role for expression level. *Circulation* 101:1707-1714, 2000.

SCIENTIFIC PUBLICATIONS (cont.)

62. **Dorn GW II**, Tepe NM, Wu G, Yatani A, Liggett SB. Mechanisms of impaired β -adrenergic receptor signaling in G α q-mediated cardiac hypertrophy and ventricular dysfunction. *Mol Pharmacol* 57:278-287, 2000.
63. De Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, **Dorn GW II**, Kitsis RN, Molkentin JD. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. *Circ Res* 86:255-263, 2000.
64. Wang X, Osinska H, **Dorn GW II**, Nieman M, Lorenz JN, Gerdes AM, Witt S, Kimball T, Gulick J, Robbins J. Mouse model of desmin-related cardiomyopathy. *Circulation* 103:2402-2407, 2001.
65. Sato Y, Kiriazis H, Yatani A, Schmidt AG, Hahn H, Ferguson DG, Sako H, Mitarai S, Honda R, Mesnard-Rouiller L, Frank KF, Beyermann B, Wu G, Fujimori K, **Dorn GW II**, Kranias EG. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. *J Biol Chem* 276:9392-9399, 2001.
66. Rogers JH, Tsirka A, Kovacs A, Blumer KJ, **Dorn GW II**, Muslin AJ. RGS4 reduces contractile dysfunction and hypertrophic gene induction in G α q overexpressing mice. *J Mol Cell Cardiol* 33:209-218, 2001.
67. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, **Dorn GW II**, MacLennan DH, and Kranias EG. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. *J Biol Chem* 276:24145-24152, 2001.
68. Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, **Dorn GW II**, Kranias EG. Interactions between phospholamban and β -adrenergic drive may lead to cardiomyopathy and early mortality. *Circulation* 103:889-896, 2001.
69. Aronow BJ, Toyokawa T, Canning A, Haghighi K, Delling U, Kranias E, Molkentin JD, **Dorn GW II**. Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy. *Physiol Genomics* 6:19-28, 2001.
70. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, **Dorn GW II**, Mochly-Rosen, D. Opposing cardioprotective actions and parallel hypertrophic effects of δ PKC and ϵ PKC. *Proc Natl Acad Sci USA* 98:11114-11119, 2001.
71. Wu G, Yussman MG, Barrett TJ, Hahn HS, Osinska H, Hillard GM, Wang X, Toyokawa T, Yatani A, Lynch RA, Robbins J, **Dorn GW II**. Increased myocardial Rab GTPase expression: A consequence and cause of cardiomyopathy. *Circ Res*. 89:1130-1137, 2001.
72. Yussman M, Toyokawa T, Odley A, Lynch R, Wu G, Colbert M, Aronow B, **Dorn GW II**. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. *Nat Med*. 8:725-730, 2002.
73. Lynch R, Wagoner L, Li S, Sparks L, Molkentin J, **Dorn GW II**. Novel and nondetected human signaling protein polymorphisms. *Physiol Genomics*. 10:159-168, 2002.
74. Wagoner LE, Craft LL, Zengel P, McGuire N, Rath Z, **Dorn GW II**, Liggett SB. Polymorphisms of the β 1-adrenergic receptor predict exercise capacity in heart failure. *Am Heart J*. 144:840-846, 2002.

SCIENTIFIC PUBLICATIONS (cont.)

75. Hahn, H, Yussman M, Toyokawa T, Marreez Y, Barrett TJ, Hilty KC, Osinska H, Robbins J, **Dorn GW II**. Ischemic protection and myofibrillar cardiomyopathy: Dose-dependent effects of *in vivo* δ PKC inhibition. *Circ Res.* 91:741-748, 2002.
76. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, **Dorn GW II**, Kranias, EG. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. *J Clin Invest.* 111:859-867, 2003.
77. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, **Dorn GW II**, MacLennan DH, Kremastinos DT, Kranias EG. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. *J Clin Invest.* 111:869-876, 2003.
78. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, **Dorn GW II**, Tallina G, Kroll TG, Nikiforov YE. *RAS* point mutations and *pax8-ppary* rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. *J Clin Endocrinology Metabolism.* 88:2318-2326, 2003.
79. Schmidt AG, Haghighi K, Frank B, Pater L, **Dorn GW II**, Walsh RA, and Kranias EG. Polymorphic SERCA2a variants do not account for inter-individual differences in phospholamban-SERCA2a interactions in human heart failure. *J Mol Cell Cardiol.* 35:867-70, 2003.
80. Inagaki K, Hahn HS, **Dorn GW II**, Mochly-Rosen D. Additive protection of the ischemic heart *ex vivo* by combined treatment with δ protein kinase C inhibitor and ϵ protein kinase C activator. *Circulation.* 108:869-75. 2003
81. Mialet PJ, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, **Dorn GW II**, Liggett SB. β_1 -adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. *Nat Med.* 9:1300-5, 2003
82. Howes AL, Arthur JF, Zhang T, Miyamoto S, Adams JW, **Dorn GW II**, Woodcock EA, Heller Brown J. Akt-mediated cardiomyocyte survival pathways are compromised by $G\alpha_q$ -induced phosphoinositide 4,5-bisphosphate depletion. *J Biol Chem.* 278:40343-40351, 2003.
83. Hahn HS, Marreez Y, Odley A, Sterbling A, Yussman MG, Hilty C, Bodi I, Liggett SB, Schwartz A, **Dorn GW II**. Protein kinase C alpha negatively regulates systolic and diastolic function in pathologic hypertrophy. *Circ Res.* 93:1111-1119, 2003.
84. Hayakawa Y, Chandra M, Miao W, Shirani J, Heller Brown J, **Dorn GW II**, Armstrong RC, Kitsis RN. Inhibition of cardiac myocyte apoptosis improves cardiac function and suppresses mortality in the peripartum cardiomyopathy of $G\alpha_q$ transgenic mice. *Circulation*, 108:3036-3041, 2003.
85. Gregory KN, Hahn H, Haghighi K, Marreez Y, Odley A, **Dorn GW II**, Kranias EG. Increased particulate partitioning of PKC reverses susceptibility of phospholamban knockout hearts to ischemic injury. *J Mol Cell Cardiol*, 36:313-318, 2004.
86. Odley A, Hahn HS, Lynch RA, Marreez Y, Osinska H, Robbins J, **Dorn GW II**. Regulation of cardiac contractility by Rab 4-modulated β_2 -adrenergic receptor recycling. *Proc Natl Acad Sci, USA* , 101:7082-7087, 2004.
87. Syed FM, Odley A, Hahn HS, Brunskill EW, Lynch RA, Marreez Y, Sanbe A, Robbins J, **Dorn GW II**. Physiological growth synergizes with pathological genes in experimental cardiomyopathy. *Circ. Res.*, 95: 1200 - 1206, 2004.

SCIENTIFIC PUBLICATIONS (cont.)

88. Syed FM, Hahn HS, Odley A, Guo Y, Vallejo J, Lynch RA, Mann DL, Bolli R, **Dorn GW II**. Proapoptotic effects of caspase-1/ICE dominate in myocardial ischemia. *Circ. Res.* 96:1103-9, 2005.
89. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, **Dorn GW II**, Robbins J, and Molkenin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. *Nature.* 434:658-62, 2005.
90. Miyamoto S, Howes AL, Adams JW, **Dorn GW II**, Heller Brown J. Ca²⁺ dysregulation induces mitochondrial depolarization and apoptosis: Role of Na⁺/Ca²⁺ exchanger and Akt. *J Biol Chem.* 280:38505-12, 2005.
91. Brunskill EW, Ehrman LA, Williams MT, Klanke J, Hammer D, Schaefer TL, Sah R, **Dorn GW II**, Potter SS and Vorhees CV. Abnormal neurodevelopment, neurosignaling and behavior in Npas3-deficient mice. *Europ J Neuroscience*, 22:1265-76, 2005.
92. Sadayappan S, Gulick J, Osinska H, Martin LA, Hahn HS, **Dorn GW II**, Klevitsky R, Seidman CE, Seidman JG and Robbins J. Cardiac myosin binding protein-C phosphorylation and cardiac function. *Circ Res.* 97:1156-63, 2005
93. Galvez AS, Brunskill EW, Marreez Y, Benner BJ, Regula KM, Kirshenbaum LA, and **Dorn GW II**. Distinct pathways regulate proapoptotic Nix and BNip3 in cardiac stress. *J Biol Chem.* 281:1442-48, 2006.
94. Haghghi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, **Dorn GW II**, Maclennan DH, Kremastinos DT, Kranias EG. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. *Proc Natl Acad Sci U S A.* 103:1388-93, 2006.
95. Zhao W, Yuan Q, Qian J, Waggoner JR, Pathak A, Chu G, Mitton B, Sun X, Jin J, Braz JC, Hahn HS, Marreez Y, Syed F, Pollesello P, Annala A, Wang HS, Schultz Jel J, Molkenin JD, Liggett SB, **Dorn GW II**, Kranias EG. The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca²⁺-ATPase superinhibition and cardiac remodeling. *Circulation.* 113:995-1004, 2006.
96. Gregory KN, Ginsburg KS, Bodi I, Hahn H, Marreez YM, Song Q, Padmanabhan PA, Mitton BA, Waggoner JR, Del Monte F, Park WJ, **Dorn GW II**, Bers DM, Kranias EG. Histidine-rich Ca binding protein: a regulator of sarcoplasmic reticulum calcium sequestration and cardiac function. *J Mol Cell Cardiol.* 40:653-665, 2006.
97. Hambleton M, Hahn H, Pleger ST, Kuhn MC, Klevitsky R, Carr AN, Kimball TF, Hewett TE, **Dorn GW II**, Koch WJ, Molkenin JD. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. *Circulation.* 114:574-82, 2006.
98. Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley A, Brunskill EW, Koch WJ, Schwartz RJ, **Dorn GW II**. Cardiac-specific ablation of GRK2 re-defines its roles in heart development and β -adrenergic signaling. *Circ Res*, 99:996-1003, 2006.
99. Yuan Q, Fan GC, Dong M, Altschafel B, Diwan A, Ren X, Hahn HH, Zhao W, Waggoner JR, Jones LR, Jones WK, Bers DM, **Dorn GW II**, Wang HS, Valdivia HH, Chu G, Kranias EG. Sarcoplasmic reticulum calcium overloading in junctin deficiency enhances cardiac contractility but increases ventricular automaticity. *Circulation.* 115:300-9, 2007.

SCIENTIFIC PUBLICATIONS (cont.)

100. Galvez AS, Diwan A, Odley AM, Hahn HS, Osinska H, Melendez JG, Robbins J, Lynch RA, Marreez Y and **Dorn GW II**. Cardiomyocyte degeneration with cardiac calpain deficiency reveals a critical role in protein homeostasis. *Circ Res.* 100:1071-8, 2007.
101. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang M-L, Segnalini P, Gu Y, Dalton ND, Latronico MVP, Høydal M, Autore C, Russo MA, **Dorn GW II**, Ellingsen Ø, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, and Condorelli G. MicroRNA-133 controls cardiac hypertrophy. *Nat Med.* 13:613-8, 2007.
102. Diwan A, Koesters AG, Odley AM, Pushkaran S, Baines CP, Spike BT, Daria D, Jegga AG, Geiger H, Aronow BJ, Molkentin JD, Macleod KF, Kalfa TA, and **Dorn GW II**. Unrestrained erythroblast development in Nix^{-/-} mice reveals a mechanism for apoptotic modulation of erythropoiesis. *Proc Natl Acad Sci, USA.* 104:6794-9, 2007.
103. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brunskill EW, **Dorn GW II**, Conway SJ, Aronow BJ, Robbins J, Molkentin JD. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. *Circ Res.* 101:313-21, 2007.
104. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, **Dorn GW II**, Liao JK. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. *Circulation.* 115:3197-204, 2007.
105. Nakamura T, Colbert M, Krenz M, Molkentin JD, Hahn HS, **Dorn GW II** and Robbins J. Mediating ERK1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. *J Clin Invest.* 117:2123-32, 2007.
106. Liggett SB, Kelly RJ, Parekh RR, Benner BJ, Hahn HS, Matkovich SJ, Syed FM, Galvez AS, Case KL, McGuire N, Odley AM, Sparks Li, Kardia SLR, and **Dorn GW II**. A functional polymorphism of the *Gαq (GNAQ)* gene is associated with accelerated mortality in African American heart failure. *Hum Mol Genet,* 16:2740-50, 2007.
107. Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, Koesters AG, Li H, Kirshenbaum LA, Hahn HS, Robbins J, Jones WK, and **Dorn GW II**. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains post-infarction remodeling. *J Clin Invest,* 117: 2825-2833, 2007.
108. Shi J, Zhang YW, Summers LJ, **Dorn GW II**, and Wei L. Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophy. *J Mol Cell Cardiol.* 44:551-60, 2008.
109. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN and **Dorn GW II**. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. *Circulation,* 117:396-404, 2008.
110. Haghighi K, Chen G, Sato Y, Fan G-C, He S, Kolokathis F, Pater L, Paraskevaidis I, Jones WK, **Dorn GW II**, Kremastinos DT, and Kranias EG. A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids. *Hum Mutat.* 29:640-7, 2008.
111. Chen G, Zhou X, Nicolaou P, Rodriguez P, Song G, Mitton B, Pathak A, Zachariah A, Fan GC, **Dorn GW II**, and Kranias EG. A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to β-adrenergic stimulation. *FASEB J,* 22:1790-6, 2008.

SCIENTIFIC PUBLICATIONS (cont.)

112. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, Spertus JA, Koch WJ, Kardias SLR, and **Dorn GW II**. A GRK-5 polymorphism that inhibits β -adrenergic receptor signaling is protective in heart failure. *Nat Med*, 14:510-7, 2008.
113. Ozgen N, Obreztkhikova M, Guo J, Elouardighi H, **Dorn GW II**, Wilson BA, and Steinberg SF. Protein kinase D links Galpha q-coupled receptors to CREB-S133 phosphorylation in the heart. *J Biol Chem*. 283:17009-19, 2008.
114. Pott C, Willkomm L, Grafweg S, Bölck B, **Dorn GW II**, Schwinger RH, and Brixius K. Reduced troponin I phosphorylation and increased Ca(2+)-dependent ATP-consumption in triton X-skinned fiber preparations from Galphaq overexpressor mice. *Mol Cell Biochem*. 314:133-41, 2008.
115. Diwan A, Koesters AG, Capella D, Geiger H, Kalfa TA, and **Dorn GW II**. Targeting erythroblast-specific apoptosis in experimental anemia. *Apoptosis*. 13:1022-30, 2008.
116. Arvanitis DA, Sanoudou D, Kolokathis F, Vafiadaki E, Papalouka V, Kontrogianni-Konstantopoulos A, Theodorakis GN, Paraskevaidis IA, Adamopoulos S, **Dorn GW II**, Kremastinos DT, and Kranias EG. The Ser96Ala variant in histidine-rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy. *Eur Heart J*, 29:2514-25, 2008.
117. Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, Degeorge BR Jr, Matkovich S, Houser SR, Most P, Eckhart AD, **Dorn GW II**, and Koch WJ. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. *Circ Res*. 103:413-22, 2008.
118. Cohn HI, Harris DM, Pesant S, Pfeiffer M, Zhou RH, Koch WJ, **Dorn GW II**, Eckhart AD. Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances α 1DAR constriction. *Am J Physiol Heart Circ Physiol*. 295:H1695-704, 2008.
119. Nicolaou P, Knöll R, Haghighi K, Fan GC, **Dorn GW II**, Hasenfuß G, Kranias EG. A human mutation in the anti-apoptotic heat shock protein 20 abrogates its cardioprotective effects. *J Biol Chem*. 283:33465-33471, 2008.
120. Kardias SL, Kelly RJ, Keddache MA, Aronow BJ, Grabowski GA, Hahn HS, Case KL, Wagoner LE, **Dorn GW II**, Liggett SB. Multiple interactions between the alpha2C- and beta1-adrenergic receptors influence heart failure survival. *BMC Med Genet*. 9:93, 2008.
121. Sheikh F, Raskin A, Chu PH, Lange S, Domenighetti AA, Zheng M, Liang X, Zhang T, Yajima T, Gu Y, Dalton ND, Mahata SK, **Dorn GW II**, Heller-Brown J, Peterson KL, Omens JH, McCulloch AD, Chen J. An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. *J Clin Invest*. 118:3870-8, 2008.
122. Petrashevskaya N, Gaume BR, Muhlbachler KA, **Dorn GW II**, Liggett SB. Bitransgenesis with β 2-adrenergic receptors or adenylyl cyclase fails to improve β -adrenergic receptor cardiomyopathy. *Clin Transl Sci*. 1:221-227, 2008.
123. Chen G, Zhou X, Pathak A, **Dorn GW II**, Kranias EG. The human G147D-protein phosphatase 1 inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure. *Cardiology*. 112:224-231, 2009.
124. Diwan A, Matkovich SJ, Yuan Q, Zhao W, Yatani A, Heller-Brown J, Molkenstein JD, Kranias EG, **Dorn GW II**. Endoplasmic reticulum-mitochondrial crosstalk in Nix-mediated murine cell death. *J Clin Invest*. 119:203-212, 2009.

SCIENTIFIC PUBLICATIONS (cont.)

125. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies KB, **Dorn GW II**. Reciprocal regulation of myocardial miR and mRNA in human cardiomyopathy and reversal of the miR signature by biomechanical support. *Circulation*, 119:1263-71, 2009.
126. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SLR, **Dorn GW II**. Clinical and genetic modifiers of long-term survival in heart failure. *J Am Coll Cardiol*, 54:432-44, 2009.
127. Sosnovik DE, Nahrendorf M, Panizzi P, Matsui T, Aikawa E, Dai G, Li L, Reynolds F, **Dorn GW II**, Weissleder R, Josephson L, Rosenzweig A. Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. *Circ Cardiovasc Imaging* 2:468-75, 2009
128. Matkovich SJ, van Booven DJ, Hindes A, Kang MY, Druley TE, Vallania FLM, Mitra RB, Reilly MP, Cappola TP, **Dorn GW II**. Cardiac signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with disease. *J Clin Invest*, 120:280-9, 2010.
129. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM, **Dorn GW II**. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure overloaded adult hearts. *Circ Res*, 106:166-75, 2010.
130. Nijboer CH, Heijnen CJ, Willemen HL, Groenendaal F, **Dorn GW II**, Bel FV, Kavelaars A. Cell-specific roles of GRK2 in onset and severity of hypoxic-ischemic brain damage in neonatal mice. *Brain Behav Immun*, 24:420-6, 2010.
131. Cappola TP, Li M, He J, Ky B, Gilmore J, Qu L, Keating B, Reilly M, Kim CE, Glessner J, Frackelton E, Hakonarson H, Syed F, Hindes A, Matkovich SJ, Cresci S, **Dorn GW II**. Common variants in HSPB7 and FRMD4B associated with advanced heart failure. *Circ Cardiovasc Genet*, 3:147-54, 2010.
132. Qin F, Lennon-Edwards S, Lancel S, Biolo A, Siwik DA, Pimentel DR, **Dorn GW II**, Kang YJ, Colucci WS. Cardiac-specific Overexpression of Catalase Identifies Hydrogen Peroxide-dependent and Independent-phases of Myocardial Remodeling, and Prevents the Progression to Overt Heart Failure in $G\alpha q$ -overexpressing Transgenic Mice. *Circ Heart Fail*, 3:306-13, 2010.
133. Eijkelkamp N, Heijnen CJ, Willemen HL, Deumens R, Joosten EA, Kleibeuker W, den Hartog IJ, van Velthoven CT, Nijboer C, Nassar MA, **Dorn GW II**, Wood JN, Kavelaars A. GRK2: A Novel Cell-Specific Regulator of Severity and Duration of Inflammatory Pain. *J Neuroscience*, 30:2138-49, 2010.
134. **Dorn GW II**. Mitochondrial Pruning by Nix and BNip3: An essential function for cardiac-expressed death factors. *J Cardiovasc Transl Res*, 3:374-83, 2010.
135. Lympelopoulos A, Rengo G, Gao E, Ebert SN, **Dorn GW II**, Koch WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. *J Biol Chem*, 285:16378-86, 2010.
136. Matkovich SJ, Zhang Y, van Booven D, **Dorn GW II**. Deep mRNA sequencing for in vivo functional analysis of cardiac transcriptional regulators: Application to $G\alpha q$. *Circ Res*, 106:1459-67, 2010.

SCIENTIFIC PUBLICATIONS (cont.)

137. Chen Y, Lewis W, Diwan A, Cheng E H-Y, Matkovich SJ, **Dorn GW II**. Dual autonomous mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy. *Proc Natl Acad Sci USA (Feature Article)* 107:9035-42, 2010.
138. Fujimoto K, Chen Y, Polonsky KS, **Dorn GW II**. Targeting cyclophilin D and the mitochondrial permeability transition enhances β -cell survival and prevents diabetes in Pdx1 deficiency. *Proc Natl Acad Sci USA*, 107:10214-9, 2010.
139. Matkovich SJ, Van Booven DJ, Cappola TP, **Dorn GW II**. Association of an intronic, but not any exonic, FRMD4B sequence variant and heart failure. *Clin Transl Sci* 3:134-9, 2010.
140. Ding W-Y, Ni H-M, Li M, Liao Y, Chen X, Stolz DB, **Dorn GW II**, Tin X-M. Nix is critical to two distinct phases of mitophagy: Reactive Oxygen Species (ROS)-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondria pruning. *J Biol Chem* 285:27879-90, 2010.
141. Willemsen HL, Eijkelkamp N, Wang H, Dantzer R, **Dorn GW II**, Kelley KW, Heijnen CJ, Kavelaars A. Microglial GRK2 determines duration of peripheral IL-1 β -induced hyperalgesia: Contribution of spinal cord CX3CR1, p38 and IL-1 signaling. *Pain* 150:550-60, 2010.
142. Cresci S, Huss JM, Beitelshes AL, Jones PG, Minton MR, **Dorn GW II**, Kelly DP, Spertus JA, McLeod HL. A PPAR α promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. *PLoS ONE* 5:e12584, 2010.
143. Kang MY, Zhang Y, Matkovich SJ, Diwan A, Chishti AH, and **Dorn GW II**. Receptor-Independent Cardiac Protein Kinase C α Activation by Calpain-Mediated Truncation of Regulatory Domains. *Circ Res* 107:903-12, 2010.
144. Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, Asosingh K, Balaban R, Bauer N, Bhattacharya J, Bogaard H, Choudhary G, **Dorn GW II**, Dweik R, Fagan K, Fallon M, Finkel T, Geraci M, Gladwin MT, Hassoun PM, Humbert M, Kaminski N, Kawut SK, Loscalzo J, McDonald D, McMurtry IF, Newman J, Nicolls M, Rabinovitch M, Shizuru J, Oka M, Polgar P, Rodman D, Schumacker P, Stenmark K, Tudor R, Voelkel N, Sullivan E, Weinshilboum R, Yoder MC, Zhao Y, Gail D, Moore TM. Strategic Plan for Lung Vascular Research: An NHLBI-ORDR Workshop Report. *Am J Respir Crit Care Med*, 182:1554-62, 2010.
145. Fujimoto K, Ford EL, Tran H, Wice BM, Crosby SD, **Dorn GW II**, Polonsky KS. Interrupting Nix upregulation in Pdx1 deficiency prevents apoptotic and necrotic beta-cell death, and murine diabetes. *J Clin Invest*, 120:4031-9, 2010.
146. Patial S, Saini Y, Parvataneni S, Appledorn DM, **Dorn GW II**, Lapres JJ, Amalfitano A, Senagore P, Parameswaran N. Myeloid-specific GPCR kinase-2 negatively regulates NF κ B1p105-ERK pathway and limits endotoxemic shock in mice. *J Cell Physiol*, 226:627-37 2011.
147. Lanktree MB, Guo Y, Murtaza M, et al. Meta-analysis of dense genecentric association studies reveals common and uncommon variants associated with height. *Am J Hum Genet*. 88:6-18, 2011.
148. Matkovich SJ, van Booven DJ, Eschenbacher WH, **Dorn GW II**. RISC RNA sequencing for context-specific identification of in vivo miR targets. *Circ Res*, 108:18-26, 2011.
149. **Dorn GW II**, Clark CF, Eschenbacher WH, Kang M-Y, Engelhard JT, Warner SJ, Matkovich SJ, Jowdy CC. MARF and Opal control mitochondrial and cardiac function in *Drosophila*. *Circ Res*, 108:12-17, 2011.
150. Cappola TP, Matkovich SJ, Wang Wei, Van Booven DJ, Li M, Wang X, Qu L, Sweitzer NK, Fang JC, Reilly M, Hakonarson H, Nerbonne JM, **Dorn GW II**. Loss-of-function DNA sequence variant in the *CLCNKA* chloride channel implicates the cardio-renal axis in inter-individual heart failure risk variation. *Proc Natl Acad Sci USA*, 108:2456-61, 2011.

SCIENTIFIC PUBLICATIONS (cont.)

151. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintrón M, Chen T, Marcinek DJ, **Dorn GW II**, Kang YJ, Prolla TA, Santana LF, Rabinovitch PS. Mitochondrial Oxidative Stress Mediates Angiotensin II-Induced Cardiac Hypertrophy and Gαq Overexpression-Induced Heart Failure. *Circ Res*, 108:837-46, 2011.
152. Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ, Gold J, Gumpert A, Chen M, Otis NJ, **Dorn GW II**, Trimarco B, Iaccarino G, Koch WJ. GRK2 activity impairs cardiac glucose uptake and promotes insulin resistance following myocardial ischemia. *Circulation*, 123:1953-62, 2011.
153. Rodriguez G, Ueyama T, Ogata T, Czernuszewicz G, Tan Y, **Dorn GW II**, Bogaev R, Amano K, Oh H, Matsubara H, Willerson JT, Marian AJ. Molecular Genetic and Functional Characterization Implicate Muscle-Restricted Coiled-Coil Gene (MURC) as a Causal Gene for Familial Dilated Cardiomyopathy. *Circ Cardiovasc Genet*, 4:349-58, 2011.
154. Zhang Y, Matkovich SJ, Duan W, Gold JJ, Koch WJ, **Dorn GW II**. Nuclear effects of GRK5 on HDAC5-regulated gene transcription in heart failure. *Circ Heart Fail*, 4:659-68, 2011.
155. Xiang SY, Vanhoutte D, Del Re DP, Purcell NH, Ling H, Banerjee I, Bossuyt J, Lang RA, Zheng Y, Matkovich SJ, Miyamoto S, Molkentin JD, **Dorn GW II**, Brown JH. RhoA protects against ischemia/reperfusion injury. *J Clin Invest*, 121:3269-76, 2011.
156. Zhang Y, Matkovich SJ, Diwan A, Kang M-Y, **Dorn GW II**. Receptor-independent PKCα signaling by calpain-generated free catalytic domains induces HDAC5 nuclear export and regulates cardiac transcription. *J Biol Chem*, 286:26943-51, 2011.
157. Lin CH, Kurup S, Herrero P, Schechtman KB, Eagon JC, Klein S, Dávila-Román VG, Stein RI, **Dorn GW II**, Gropler RJ, Waggoner AD, Peterson LR. Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss. *Obesity* 19:1804-12, 2011.
158. Razani B, Zhang H, Schulze PC, Schilling JD, Verbsky J, Lodhi IJ, Topkara VK, Feng C, Coleman T, Kovacs A, Kelly DP, Saffitz JE, **Dorn GW II**, Nichols CG, Semenkovich CF. Fatty acid synthase modulates homeostatic responses to myocardial stress. *J Biol Chem*, 286:30949-61, 2011.
159. Porrello ER, Johnson BA, Aurora AB, Simpson E, Nam YJ, Matkovich SJ, **Dorn GW II**, van Rooij E, Olson EN. miR-15 family regulates postnatal mitotic arrest of cardiomyocytes. *Circ Res*, 109:670-9, 2011.
160. Arnon TI, Xu Y, Lo C, Pham T, An J, Coughlin S, **Dorn GW II**, and Cyster JG. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction for blood. *Science*, 333:1891-1903, 2011.
161. Chen Y, Liu Y, **Dorn GW II**. Mitochondrial fusion is essential for organelle function and cardiac homeostasis. *Circ Res*, 109:1327-31, 2011.
162. Fusco A, Santulli G, Sorriento D, Cipolletta E, Garbi C, **Dorn GW II**, Trimarco B, Feliciello A, Iaccarino G. Mitochondrial localization unveils a novel role for GRK2 in organelle biogenesis. *Cell Signal*, 24:468-75, 2012.
163. Zhu W, Petrashevskaya N, Ren S, Zhao A, Chakir K, Gao E, Chuprun JK, Wang Y, Talan M, **Dorn GW II**, Lakatta EG, Koch WJ, Feldman AM, Xiao R-P. Gi-biased β2AR signaling links GRK2 upregulation to heart failure. *Circ Res*, 110:265-74, 2012.
164. Saxena R, Elbers CC, Guo Y, et al. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. *Am J Hum Genet*, 90:410-25, 2012.

SCIENTIFIC PUBLICATIONS (cont.)

165. **Dorn GW II**, Matkovich SJ, Eschenbacher WH, Zhang Y. A human 3' miR-499 mutation alters cardiac mRNA targeting and function. *Circ Res*, 110:958-67, 2012.
166. Cresci S, **Dorn GW II**, Jones PG, Beitelshes AL, Li AY, Lensini PA, Province MA, Spertus JA, Lanfear DE. Adrenergic-pathway gene variants influence β -blocker-related outcomes after acute coronary syndrome in a race-specific manner. *J Am Coll Cardiol*. 60:898-907, 2012.
167. Raake PW, Zhang X, Vinge LE, Brinks H, Gao E, Jaleel N, Li Y, Tang M, Most P, **Dorn GW II**, Houser SR, Katus HA, Chen X, Koch WJ. Cardiac GRK2 ablation induces a novel Ca^{2+} handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. *Circulation*, 125:2108-18, 2012.
168. Whelan R, Konstantinidis K, Wei A-C, Chen Y, Reyna DE, Jha S, Yang Y, Calvert JW, Lindsten T, Thompson CB, Crow M, Gavathiotis E, **Dorn GW II**, O'Rourke B, Kitsis RN. Bax regulates primary necrosis through mitochondrial dynamics. *Proc Nat Acad Sci, USA*. 109:6566-7, 2012.
169. Glick DV, Zhang W, Beaton M, Marsboom G, Gruber M, Simon MC, Hart J, **Dorn GW II**, Brady MJ, Macleod K. BNip3 regulates mitochondrial function and lipid metabolism in the liver. *Mol Cell Biol*, 32:2570-48, 2012.
170. Lee MJ, Kim DE, Zakrzewska A, Yoo YD, Kim S, Kim ST, Seo JW, Lee YS, **Dorn GW II**, Oh UT, Kim BY, Kwon YT. Characterization of the arginylation branch of the N-End Rule Pathway in G-protein-mediated proliferation and signaling of cardiomyocytes. *J Biol Chem*, 287:24043-52, 2012.
171. Tao W, Shi J, **Dorn GW II**, Wei L, Rubart M. Spatial variability in T-tubule and electrical remodeling of left ventricular epicardium in mouse hearts with transgenic Gaq overexpression-induced pathological hypertrophy. *J Mol Cell Cardiol*, 53:409-19, 2012.
172. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, **Dorn GW II**. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. *Circ Res*, 111:521-31, 2012.
173. Chen Y, Csordas G, Jowdy C, Schneider TG, Wang W, Liu Y, Kohlhaas M, Meiser M, Bergem S, Nerbonne JM, **Dorn GW II***, Maack C* (* co-contributing authors). Mitofusin 2-containing mitochondrial-reticular microdomains direct rapid cardiomyocyte bioenergetic response via inter-organelle Ca^{2+} crosstalk. *Circ Res*, 111:863-75, 2012.
174. Eschenbacher WH, Song M, Chen Y, Zhao P, Jowdy CC, Engelhard JT, **Dorn GW II**. Two rare human mitofusin 2 mutations alter mitochondrial dynamics and induce retinal and cardiac pathology in *Drosophila*. *PLoS One*, 7:e44296, 2012.
175. Hu Y, Matkovich SJ, Hecker PA, Zhang Y, Edwards JR, **Dorn GW II**. Epitranscriptional orchestration of genetic reprogramming is an emergent property of stress-regulated cardiac microRNAs. *Proc Nat Acad Sci, USA*, 109:19864-9, 2012.
176. Guo Y, Lanktree MB, Taylor KC, et al. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. *Hum Mol Genet*, 22:148-201, 2013.
177. Cao DJ, Jiang N, Blagg A, Johnstone JL, Gondalia R, Oh M, Luo X, Yang KC, Shelton JM, Rothermel BA, Gillette TG, **Dorn GW II**, Hill JA. Mechanical Unloading Activates FoxO3 to Trigger Bnip3-Dependent Cardiomyocyte Atrophy. *J Am Heart Assoc*. 2:e000016, 2013.
178. Matkovich SJ, Hu Y, **Dorn GW II**, Regulation of cardiac microRNAs by cardiac microRNAs. *Circ Res*, 113:62-71, 2013.
179. Chen Y and **Dorn GW II**. PINK1-phosphorylated Mitofusin 2 is a Parkin receptor for culling damaged mitochondria. *Science*, 340:471-5, 2013.

SCIENTIFIC PUBLICATIONS (cont.)

180. Kasahara A, Cipolat S, Chen Y, **Dorn GW II***, Scorrano L* (* co-contributing authors). Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin/notch signaling. *Science*, 342:734-7, 2013.
181. Chen Y, Decker KF, Zheng D, Matkovich SJ, Jia L, and **Dorn GW II**. A nuclear-targeted alternately spliced Nix/Bnip3L isoform modifies NF- κ B mediated cardiac transcription. *J Biol Chem*, 288:15455-65, 2013.
182. Vasudevan NT, Mohan ML, Gupta MK, Martelli EE, Hussain AK, Qin Y, Chandrasekharan UM, Young D, Feldman AM, Sen S, **Dorn GW II**, Dicorleto PE, Naga Prasad SV. G $\beta\gamma$ independent recruitment of G-protein coupled receptor kinase 2 drives TNF α -induced cardiac beta-adrenergic receptor dysfunction. *Circulation*, 128:377-87, 2013.
183. Fan Q, Chen M, Zuo L, Shang X, Huang MZ, Ciccarelli M, Raake P, Brinks H, Chuprun KJ, **Dorn GW II**, Koch WJ, Gao E. Myocardial ablation of G protein-coupled receptor kinase 2 (GRK2) decreases ischemia/reperfusion injury through an anti-intrinsic apoptotic pathway. *PLoS One*, 8:e66234, 2013.
184. Ciccarelli M, Sorriento D, Franco A, Fusco A, Del Giudice C, Annunziatam R, Cipolletta E, Monti MG, **Dorn GW II**, Trimarco B, Iaccarino G. Endothelial GRK2 regulates vascular homeostasis through the control of free radical oxygen species. *Atheroscler Thromb Vasc Biol*, 33:2415-24, 2013.
185. Sorriento D, Fusco A, Ciccarelli M, Rungi A, Anastasio A, Carillo A, **Dorn GW II**, Trimarco B, Iaccarino G. Mitochondrial G protein coupled receptor kinase 2 regulates proinflammatory responses in macrophages. *FEBS Lett*, 587:3487-94 2013.
186. Rivas V, Carmona R, Muñoz-Chápuli R, Mendiola M, Nogués L, Reglero C, Miguel-Martín M, García-Escudero R, **Dorn GW II**, Hardisson D, Mayor F Jr, Penela P. Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. *J Clin Invest*, 123:4714-30, 2013.
187. Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, **Dorn GW II**, French AR, Fehniger TA. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. *J Immunol*, 191:504-13, 2013.
188. Bhandari P, Song M, Chen Y, Burelle Y, **Dorn GW II**. Mitochondrial contagion induced by Parkin deficiency in *Drosophila* hearts and its containment by suppressing mitofusin. *Circ Res* 114:257-65, 2014.
189. Chen S, Puthanveetil P, Feng B, Matkovich SJ, **Dorn GW II**, Chakrabarti S. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. *J Cell Mol Med*, 18:415-21, 2014.
190. Puckelwartz M, Pesce L, Nelakuditi V, Dellefave-Castillo L, Golbus J, Day S, Cappola T, **Dorn GW II**, Foster I, McNally E. Supercomputing for the parallelization of whole genome analysis. *Bioinformatics*, 30:1508-13, 2014.
191. Song M, Chen Y, Gong G, Murphy E, Rabinovitch P, **Dorn GW II**. Super-suppression of mitochondrial ROS signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy. *Circ Res*, 115:348-53, 2014.
192. Matkovich SJ, Edwards JR, Grossenheider TC, de Guzman Strong C, **Dorn GW II**. Epigenetic coordination of embryonic heart transcription by dynamically regulated lncRNAs. *Proc Natl Acad Sci USA*, 111:12264-9, 2014.

193. Danielli A, Maslov K, Garcia-Urbe A, Winkler AM, Li C, Wang L, Chen Y, **Dorn GW II**, Wang L. Label-free photoacoustic nanoscopy. *J Biomed Opt*, 19:86006, 2014.

SCIENTIFIC PUBLICATIONS (cont.)

194. Chen Y, Sparks M, Bhandari P, Matkovich SJ, **Dorn GW II**. Mitochondrial genome linearization is a causative factor for cardiomyopathy in mice and *Drosophila*. *Antioxid Redox Signal*, 21:1949-59, 2014.
195. Dhingra R, Margulets V, Chowdhury SR, Thliveris J, Jassal D, Fernyhough P, **Dorn GW II**, Kirshenbaum LA. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. *Proc Natl Acad Sci USA*, 111:E5537-44, 2014.
196. Song M, Mihara K, Chen Y, Scorrano L, **Dorn GW II**. Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. *Cell Metab*, 21:273-85, 2015.
197. Bhandari P, Song M, **Dorn GW II**. Dissociation of mitochondrial from sarcoplasmic reticular stress in *Drosophila* cardiomyopathy induced by molecularly distinct mitochondrial fusion defects. *J Mol Cell Cardiol*, 80C:71-80, 2014.
198. Picard M, McManus M, Csordas G, Varnai P, **Dorn GW II**, Williams D, Hajnoczky G, Wallace DC. Trans-mitochondrial coordination of cristae at regulated membrane junctions. *Nat Commun*, 6:6259, 2015.
199. Westenbrink BD, Ling H, Miyamoto S, Divakaruni A, Gray CB, Zambon AC, Dalton ND, Peterson K, Gu Y, Matkovich SJ, Murphy AN, **Dorn GW II**, Heller Brown J. Mitochondrial reprogramming induced by CaMKII δ mediates hypertrophy decompensation. *Circ Res*, 116:e28-39, 2015.
200. Song M, Matkovich SJ, Zhang Y, Hammer DJ, and **Dorn GW II**. Combined cardiomyocyte PKC δ and PKC ϵ gene deletion uncovers their central role in restraining developmental and reactive heart growth. *Sci Signal*, 8:ra39, 2015.
201. Song M, Guong G, Burelle Y, Gustafsson AB, Kitsis RN, Matkovich SJ, and **Dorn GW II**. Interdependence of Parkin-mediated mitophagy and mitochondrial fission in adult mouse hearts. *Circ Res*, 117:346-51, 2015.
202. Gong G, Song M, Csordas G, Kelly DP, Matkovich SJ, and **Dorn GW II**. Parkin-mediated mitophagy directs perinatal cardiac metabolic maturation in mice. *Science*, 350:aad2459, 2015.
203. Matkovich SJ, **Dorn GW II**, Grossenheider TC, Hecker PA. Cardiac disease status dictates functional mRNA targeting profiles of individual microRNAs. *Circ Cardiovasc Genet*, 8:774-84, 2015.
204. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, 12:1-222, 2016.
205. Murphy E, Ardehali H, Balaban RS, DiLisa F, **Dorn GW II**, et al. Mitochondrial Function, Biology, and Role in Disease: A Scientific Statement From the American Heart Association. *Circ Res*, 118:1960-91, 2016.
206. Hall AR, Burke N, Dongworth RK, Kalkhoran SB, Dyson A, Vicencio JM, **Dorn GW II**, Yellon DM, Hausenloy DJ. Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction. *Cell Death Dis*. 7:e2238, 2016.
207. O'Sullivan TE, Geary CD, Weizman OE, Geiger TL, Rapp M, **Dorn GW II**, Overholtzer M, Sun JC. Atg5 is essential for the development and survival of innate lymphocytes. *Cell Rep*, 15:1910-19, 2016.
208. Tol MJ, Ottenhoff R, van Eijk M, Zelcer N, Aten J, Houten SM, Geerts D, van Roomen C, Bierlaagh MC, Scheij S, Hoeksema MA, Aerts JM, Bogan JS, **Dorn GW II**, Argmann CA,

Gerald W. Dorn II, MD

28

Verhoeven AJ. A PPAR γ -Bnip3 axis couples adipose mitochondrial fusion-fission balance to systemic insulin sensitivity. *Diabetes*, 65:2591-605, 2016.

SCIENTIFIC PUBLICATIONS (cont.)

209. Franco A, Kitsis RN, Fleischer JA, Gavathiotis E, Kornfeld OS, Gong G, Biris N, Benz A, Qvit N, Donnelly SK, Chen Y, Mennerick S, Hodgson L, Mochly-Rosen D, **Dorn GW II**. Correcting mitochondrial fusion by manipulating mitofusin conformations. *Nature* 540:74-79, 2016.
210. Naon D, Zaninelo M, Giacomello M, Varanita T, Grespi F, Lakshminaranayan S, Serafini A, Semenzato M, Herkenne S, Hernandez-Alvarez MI, Zorzano A, de Stafani D, **Dorn GW II**, Scorrano L. Critical reappraisal confirms that Mitofusin 2 is an endoplasmic reticulum-mitochondria tether. *Proc Natl Acad Sci, USA*. 113:11249-54, 2016.
211. Hammerling BC, Najor RH, Cortez MQ, Shires SE, Leon LJ, Gonzalez ER, Boassa D, Phan S, Thor A, Jimenez RE, Li H, Kitsis RN, **Dorn GW II**, Sadoshima J, Ellisman MH, Gustafsson ÅB. A Rab5 endosomal pathway mediates Parkin-dependent mitochondrial clearance. *Nat Commun* 8:14050, 2017.
212. Speir M, Vogrin A, Seidi A, Abraham G, Hunot S, Han Q, **Dorn GW II**, Masters SM, Flavell R, Vice JE, Naderer T. Legionella pneumophila strain 130b evades macrophage cell death independent of the effector SidF in the absence of flagellin. *Front Cell Infect Micro*, 7:35 doi: 10.3389/fcimb.2017.00035, 2017.
213. Beikoghli Kalkhoran S, Hall AR, White IJ, Cooper J, Fan Q, Ong SB, Hernández-Reséndiz S, Cabrera-Fuentes H, Chinda K, Chakraborty B, **Dorn GW II**, Yellon DM, Hausenloy DJ. Assessing the effects of mitofusin 2 deficiency in the adult heart using 3D electron tomography. *Physiol Rep*. 5: e13437, 2017.
214. Song M, Franco A, Fleischer JA, Zhang L, **Dorn GW II**. Abrogating mitochondrial dynamics in mouse hearts accelerates mitochondrial senescence. *Cell Metabol*. 26:872-885, 2017.
215. Xu H, **Dorn GW II**, Shetty A, Parihar A, Dave T, Robinson SW, Gottlieb SS, Donahue MP, Tomaselli GF, Kraus WE, Mitchell BD, Liggett SG. A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans. *J Pers Med*. 8:11 doi:10.3390/jpm8010011, 2018.
216. Rocha AG, Franco A, Krezel AM, Runsey JM, Alberti JM, Knight WC, Biris N, Zacharioudakis E, Janetka JW, Baloh RH, Kitsis RN, Mochly-Rosen D, Townsend RR, Gavathiotis E, **Dorn GW II**. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot Marie Tooth disease type 2A. *Science*, 360: 336-341, 2018.
217. Franco A, Zhang L, Matkovich SJ, Kovacs A, **Dorn GW II**. G-protein receptor kinases 2, 5, and 6 modulate Smoothed-GATA transcriptional crosstalk in fetal mouse hearts. *J Mol Cell Cardiol*, 121:60-68, 2018.
218. Von Schulze A, McCoin CS, Onyekere C, Allen JA, Geiger OC, **Dorn GW II**, Morris EM, Thyfault JP. Hepatic mitochondrial adaptations to physical activity: impact of sexual dimorphism, PGC1 α , and BNIP3 mediated mitophagy. *J Physiol*, 596:6157-71, 2018.
219. Zhou Y, Carmona S, Muhammad AKMG, Bell S, Landeros J, Vazquez M, Ho R, Franco A, Lu B, **Dorn GW II**, Wang S, Lutz CM, Baloh RH. Restoring mitofusin balance prevents axonal degeneration in CMT2A model mice. *J Clin Invest*, 130:1756-71, 2019.
220. Thai PN, Seidlmayer LK, Miller C, Ferrero M, **Dorn GW II**, Schaefer S, Bers DM, Dedkova EN. Mitochondrial quality control in aging and heart failure: Influence of ketone bodies and mitofusin stabilizing-peptides. *Front Physiol*, 10:382. doi:10.3389/fphys.2019.00382, 2019.
221. Seidlmayer LK, Mages C, Berbner A, Eder-Negrin P, Arias-Loza P, Kaspar M, Song M, **Dorn GW II**, Kohlhaas M, Frantz S, Maack C, Gerull B, Dedkova EN. Mitofusin 2 is essential for IP3-

- mediated SR/mitochondrial metabolic feedback in ventricular myocytes. *Front Physiol*, 10:733. doi:10.3389/fphys.2019.00733, 2019.
222. McCoin CS, Von Schulze A, Allen J, Fuller KNZ, Xia Q, Koestler DC, Houchen CJ, Maurer A, **Dorn GW II**, Shankar K, Morris EM, Thyfault JP. Sex modulates hepatic mitochondrial adaptations to high-fat diet and physical activity. *Am J Physiol Endocrinol Metab* 317:E298-311, 2019.

CHAPTERS, EDITORIALS AND INVITED REVIEWS

1. **Dorn GW II**, Halushka PV. Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease. *Ration Drug Ther* 19:1-7, 1985.
2. Halushka PV, Mais DE, **Dorn GW II**, Liel N. A role for thromboxane A₂ in cardiovascular and renal diseases? *Emory University Journal of Medicine* 2:19-32, 1988.
3. **Dorn GW II**, Hauger DA. Platelet and vascular endothelial cell biology in atherosclerosis. In *Contemporary Management in Internal Medicine. Update on Hemostasis*. Boldt DH (ed.) Churchill Livingstone, New York, 3-40, 1990.
4. Lewis W, **Dorn GW II**. Cardiac Structure and Function in HIV-Infected Children. *N Engl J Med* 328:513-514, 1993.
5. **Dorn GW II**. *Thrombosis and Hemorrhage*. Book Review: *Circulation* 90:(5)2580, 1994.
6. **Dorn GW II**. Role of thromboxane A₂ in mitogenesis of vascular smooth muscle cells. *Inflammation Research, Agents and Actions Supplements* 48:42-62, 1997.
7. Walsh RA, **Dorn GW II**. Growth and hypertrophy of the heart and blood vessels. In *Hurst's THE HEART*, 9th Edition, Chapter 6:155-168, 1997.
8. **Dorn GW II**. Isolated myocyte mechanics and calcium transients. In *Cardiovascular Physiology in the Genetically Engineered Mouse*, Chapter 4:55-68, 1998.
9. **Dorn GW II**, Brown JH. Gq signaling in cardiac adaptation and maladaptation. *Trends Cardiovasc Med* 9:26-34, 1999.
10. **Dorn GW II**. G proteins in heart disease. *Heart Failure Reviews* 4:303-310, 1999.
11. Robbins J, **Dorn GW II**. Listening for hoof beats in heart beats. *Nat Med* 6:968-970, 2000.
12. Molkenkin JD, **Dorn GW II**. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. *Annu Rev Physiol* 63:391-426, 2001.
13. **Dorn GW II**. Calcineurin inhibition in hypertrophy: Back from the dead! *Circulation* 104:9-11, 2001.
14. **Dorn GW II**, Mochly-Rosen D. Intracellular transport mechanisms of signal transducers. *Annu Rev Physiol* 64:407-429, 2002.
15. **Dorn GW II**, Mann, DL. Signaling pathways involved in left ventricular remodeling: Summation. *J Card Fail.* 8:S387-S388, 2002.
16. **Dorn GW II**. Adrenergic pathways and left ventricular remodeling. *J Card Fail.* 8:S370-S373, 2002.
17. Azhar M, Schultz Jel J, Grupp I, **Dorn GW II**, Meneton P, Molin DG, Gittenberger-de Groot AC, Doetschman T. Transforming growth factor beta in cardiovascular development and function. *Cytokine Growth Factor Rev* 14:391-407, 2003.
18. **Dorn GW II**, Robbins J, Sugden PH. Phenotyping hypertrophy: Eschew obfuscation. *Circ Res*, 92:1171-5, 2003.
19. **Dorn GW II** and Molkenkin JD. Manipulating cardiac contractility in heart failure: Data from mice and men. *Circulation*, 109: 150-158, 2004.
20. **Dorn GW II** and Hahn HS. Genetic Factors in Cardiac Hypertrophy. *Ann N.Y. Acad. Sci.* 1015:225-237, 2004.
21. **Dorn GW II** and Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. *J. Clin. Invest.* 115:527-37, 2005.
22. **Dorn GW II**. Physiological growth and pathological genes in cardiac development and cardiomyopathy. *Trends. Cardiovasc. Medicine.* 15:185-9, 2005.
23. **Dorn GW II** and Wagoner LE. "Adrenergic receptor signaling and cardiac remodeling" in

Gerald W. Dorn II, MD

Cardiac Remodeling: Mechanisms and Treatment, Chapter 13:215-240, 2006.

32

CHAPTERS, EDITORIALS AND INVITED REVIEWS (cont.)

24. **Dorn GW II.** Containing hypertrophy with a PICOT fence. *Circ Res*, 99:228-30, 2006.
25. **Diwan A and Dorn GW II.** Decompensation of cardiac hypertrophy: Cellular mechanisms and novel therapeutic targets. *Physiology*, 22:56-64, 2007.
26. **Dorn GW II.** The fuzzy logic of physiological cardiac hypertrophy. *Hypertension*, 49:962-70, 2007.
27. **Dorn GW II.** The Gordon Wilson Lecture: Neurohormonal signaling pathways that link cardiac growth and death. *Trans Am Clin Climatol Assoc*, 118:137-52, 2007.
28. **Dorn GW II.** Myocardial Angiogenesis: It's Absence Makes the Growing Heart Founder. *Cell Metabolism*, 5:326-7, 2007.
29. **Dorn GW II.** Periostin and myocardial repair, regeneration, and recovery. *New Engl J Med*, 357:1552-4, 2007.
30. **Dorn GW II and Diwan A.** The rationale for cardiomyocyte resuscitation in myocardial salvage. *J Mol Med*, 86:1085-95, 2008.
31. **Dorn GW II and Cresci S.** The mechanistic imperative for pharmacogenomics. *Pharmacogenomics*, 9:801-3, 2008.
32. **Dorn GW II and Matkovich SJ.** Put your chips on transcriptomics. *Circulation*, 118:216-8, 2008.
33. **Dorn GW II and Liggett SB.** Pharmacogenomics of β -adrenergic receptors and their accessory signaling proteins in heart failure. *Clin and Translat Sci*, 1:255-262, 2008.
34. **Dorn GW II and Kirshenbaum LA.** Cardiac reanimation: Targeting cardiomyocyte death by Bnip3 and Bnip3L. *Oncogene*, 27:S158-167, 2008.
35. **Dorn GW II** Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodeling. *Cardiovasc Res*, 81:465-73, 2009.
36. **Dorn GW II.** Novel pharmacotherapeutics to improve post-infarction ventricular repair, recovery, and remodeling. *Nat Clin Rev Cardiol*, 6:283-91, 2009.
37. **Dorn GW II.** GRK Mythology: G-protein receptor kinases in cardiovascular disease. *J Mol Med*, 87:455-63, 2009.
38. **Dorn GW II and Cresci S.** Genome-wide association studies of coronary artery disease and heart failure: Where are we going? *Pharmacogenomics*, 10:213-23, 2009.
39. **Dorn GW II and Liggett SB.** Mechanisms of pharmacogenomic effects of genetic variation of the cardiac adrenergic network in heart failure. *Mol Pharmacol*, 76:466-80, 2009.
40. **Dorn GW II.** Having a change of heart: reversing the suicidal proclivities of cardiac myocytes. *Trans Am Clin Climatol Assoc* 120:189-98, 2009.
41. **Dorn GW II.** Pharmacogenetic profiling in the treatment of heart disease. *Transl Res* 154:295-302, 2009.
42. Condorelli G, Latronico MV, **Dorn GW II.** microRNAs in heart disease: putative novel therapeutic targets? *Eur Heart J*, 31:649-58, 2010.
43. **Dorn GW II.** Therapeutic potential of microRNAs in heart failure. *Curr Cardiol Rep*, 12:209-15, 2010.
44. **Dorn GW II.** Adrenergic signaling polymorphisms and their impact on cardiovascular disease. *Physiological Reviews*, 90:1013-62, 2010.
45. **Dorn GW II.** Refugee receptors switch sides. *Science*, 327:1586-7, 2010.

CHAPTERS, EDITORIALS AND INVITED REVIEWS (cont.)

46. **Dorn GW II.** Mechanisms of non-apoptotic programmed cell death in diabetes and heart failure. *Cell Cycle*, 9:3442-8, 2010.
47. **Dorn GW II** and Scorrano L. Two close, too close: Sarcoplasmic reticulum-mitochondrial cross-talk and cardiomyocyte fate. *Circ Res*, 107:689-699 2010.
48. **Dorn GW II.** MicroRNAs: Redefining mechanisms in cardiac disease. *J Cardiovasc Pharmacol*, 56:589-95, 2010.
49. Diwan A and **Dorn GW II.** “Molecular Basis for Heart Failure” in *Heart Failure, a companion to Braunwald’s Heart Disease*. Chapter 2, 7-31, 2011.
50. **Dorn GW II.** MicroRNAs in cardiac disease. *Transl Res*, 157:226-35, 2011.
51. **Dorn GW II.** Nix Nought Nothing: Fairy tale or real deal. *J Mol Cell Cardiol*, 51:497-500,2011.
52. **Dorn GW II.** Genetics of common forms of heart failure. *Curr Opin Cardiol* 26:204-8, 2011.
53. **Dorn GW II.** The Genomic architecture of sporadic heart failure. *Circ Res*, 108:1270-83, 2011.
54. Cappola TP and **Dorn GW II.** Clinical considerations of heritable factors in common heart failure. *Circ Cardiovasc Gen*, 4:701-9, 2011.
55. **Dorn GW II** and Kitsis RN. “Programmed Cardiomyocyte Death in Heart Disease” in *Muscle: Fundamental Biology and Mechanisms of Disease*. Chapter 31, 423-446, 2012.
56. **Dorn GW II.** Decoding the cardiac message. *Circ Res*, 110:755-63, 2012.
57. **Dorn GW II.** Resolving a catch-22 in cardiac gene regulation. *Circulation*, 125:2695-7, 2012.
58. **Dorn GW II.** Inflammation on! Mitochondrial escape provokes cytokine storms that doom the heart. *Circ Res*, 111:271-273, 2012.
59. **Dorn GW II.** Mitochondrial dynamics in heart disease. *Biochim Biophys Acta*, 1833:233-41, 2013.
60. **Dorn GW II** and Maack C. SR and mitochondria: Calcium cross-talk between kissing cousins. *J Mol Cell Cardiol*, 55:42-9, 2013.
61. **Dorn GW II.** Molecular mechanisms that differentiate apoptosis from programmed necrosis. *Toxicol Pathol*, 41:227-34, 2013.
62. Westenbrink BD and **Dorn GW II.** Imaging the cardiac diet. *Eur J Heart Fail*, 15:123-4, 2013.
63. **Dorn GW II.** “Molecular Signaling Networks Underlying Cardiac Hypertrophy and Failure” in *Heart Failure*, Marc J Semigran and Jordan T Shin editors. Second edition, Chapter 3, 31-42, 2013.
64. **Dorn GW II.** Shared genetic risk for sclerosis of valves and vessels. *N Engl J Med*, 368:569-70, 2013.
65. **Dorn GW II.** MicroRNAs and the butterfly effect. *Cell Cycle* 12:707-8, 2013.
66. **Dorn GW II.** Mitochondrial dynamism and cardiac fate: a personal perspective. *Circ J*, 77:1370-9, 2013.
67. **Dorn GW II** miR-34a and the cardiomyopathy of senescence: SALT PNUTS, SALT PNUTS! *Cell Metab*, 17:629-30, 2013.
68. **Dorn GW II** and Matkovich SJ. Ménage à Trois: Intimate relationship between a microRNA, long noncoding RNA and mRNA. *Circ Res*, 114:1362-5, 2014.
69. **Dorn GW II.** LIPCAR: A mitochondrial lnc in the noncoding RNA chain. *Circ Res*, 114:1548-50, 2014.
70. **Dorn GW II** and McNally EM. Two Strikes and You’re Out: Gene–Gene Mutation Interactions in HCM. *Circ Res*, 115:208-210, 2014.

CHAPTERS, EDITORIALS AND INVITED REVIEWS (cont.)

71. **Dorn GW II** and Kitsis RN. The mitochondrial dynamism-mitophagy-cell death interactome: Multiple roles performed by members of a mitochondrial molecular ensemble. *Circ Res*, 116:167-182, 2015.
72. **Dorn GW II**, Song M, Walsh K. Functional implications of mitofusin 2-mediated mitochondrial-SR tethering. *J Mol Cell Cardiol*, 78C:123-128, 2015.
73. **Dorn GW II** and Matkovich SJ. Epitranscriptional regulation of cardiovascular development and disease. *J Physiol*, 593:1799-808, 2015.
74. **Dorn GW II**. Gone fission.... Diverse consequences of cardiac Drp1 deficiency. *Circ Res*, 116:225-8, 2015.
75. Song M and **Dorn GW II**. Mitoconfusion: Non-canonical functioning of dynamism factors in static mitochondria of the heart. *Cell Metab*, 21:195-205, 2015.
76. **Dorn GW II**. Cardiac regeneration – Alchemy, science, and a wee bit of magic? *J Mol Cell Cardiol* 81C:10-11, 2015.
77. Matkovich SJ and **Dorn GW II**. Deep sequencing of cardiac microRNA-mRNA interactomes in clinical and experimental cardiomyopathy. *Methods Mol Biol*, 1299:27-49, 2015.
78. **Dorn GW II**. Mitochondrial dynamism and heart disease: changing shape and shaping change. *EMBO Mol Med*, 7:865-77, 2015.
79. Shirihai O, Song M, **Dorn GW II**. How mitochondrial dynamism orchestrates mitophagy. *Circ Res*, 116:1835-49, 2015.
80. **Dorn GW II**. Great Expectations: MicroRNA-30d and cardiac resynchronization therapy. *Circulation*, 131:2172-5, 2015.
81. Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang CP, **Dorn GW II**, Thum T, Heymans S. Long noncoding RNAs in cardiac development and ageing. *Nat Rev Cardiol*, 12:346-51, 2015.
82. **Dorn GW II**, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and diseased heart. *Genes Dev*, 29:1981-91, 2015.
83. **Dorn GW II**. Parkin-dependent mitophagy in the heart. *J Mol Cell Cardiol*, 95:42-9, 2016.
84. **Dorn GW II**. Jurassic PARK2: You eat your mitochondria, and you are what your mitochondria eat. *Autophagy*, 12:610-11, 2016.
85. **Dorn GW II**. Mitochondrial fission/fusion and cardiomyopathy. *Curr Opin Genet Develop*, 38:38-44, 2016.
86. **Dorn GW II**. Central Parkin: The evolving role of Parkin in the heart. *Biochim Biophys Acta Bioenergetics*, 1857:1307-12, 2016.
87. **Dorn GW II**. Tension-time integrals and genetic cardiomyopathy: The force is with you. *Cell*, 165:1049-50, 2016.
88. **Dorn GW II**. Canon Fodder – A case for contrarian science. *Circ Res* 119:584-6, 2016.
89. Matkovich SJ, **Dorn GW II**. Feed My Heart or Eat It: miR-22 Decides. *J Am Coll Cardiol*, 68:1572-4, 2016.
90. Naon D, Zaninello M, Giacomello M, Varanita T, Grespi F, Lakshminaranayan S, Serafini A, Semenzato M, Herkenne S, Hernández-Alvarez MI, Zorzano A, De Stefani D, **Dorn GW II**, Scorrano L. Reply to Filadi et al.: Does mitofusin 2 tether or separate endoplasmic reticulum and mitochondria? *Proc Natl Acad Sci USA* 114:E2268-9, 2017.
91. Yanamandala M, Zhu W, Garry DJ, Kamp TJ, Hare JH, Jun H-W, Yoon Y-S, Bursac N, Prabhu SD, **Dorn GW II**, Boli R, Kitsis RN, Zhang J. Overcoming the roadblocks to cardiac cell therapy

- using tissue engineering. *J Am Coll Cardiol* 70:766-75, 2017.
92. **Dorn GW II.** Cardiac-specific research platforms engender novel insights into mitochondrial dynamism. *Current Opin Physiol.* 3:110-115, 2018.
 93. **Dorn GW II.** Evolving concepts of mitochondrial dynamics. *Annu Rev Physiol.* 81:1-17, 2019.
 94. Gustafsson AB and **Dorn GW II.** Evolving and expanding roles of mitophagy as a homeostatic and pathogenic process. *Physiol Rev.* 99:853-892, 2019.